Short answer
GLAUKOS Corp (GKOS) filed an 8-K current report with the SEC on November 6, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor Presentation intended for recurring discussions with investors and other stakeholders.
GLAUKOS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor Presentation intended for recurring discussions with investors and other stakeholders
- Exhibit 99.1 provides the substantive company disclosures and presentation materials
- Availability on Glaukos’ investor-relations website improves access to management’s investor messaging
Item EX-99.1 · Exhibit EX-99.1
- November 2026 investor presentation highlights 14 pipeline programs and 12 commercialized products across glaucoma, cornea, eyelid and retina markets
- 2025 topline growth 30%, with 10-year revenue CAGR of 20% and $900 million invested in R&D since 2018
- iDose TR re-administration approval in January 2026 supports recurring procedural revenue and broader adoption of sustained-release glaucoma therapy
- Epioxa launched commercially in March 2026 as the first FDA-approved epithelium-on keratoconus treatment, expanding Glaukos’ pharmaceutical opportunity
- Financial capacity remains strong: $340 million cash and equivalents, no debt as of September 30, 2026, and 88% third-quarter gross margin
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GLAUKOS Corp 8-K filings
Get the next GKOS 8-K as it lands
Follow GKOS for push alerts, or ask the research agent what this filing means.